Ireland - English - HPRA (Health Products Regulatory Authority)

milpharm limited - cefuroxime axetil (amorphous) - film coated tablet - 500 milligram - cephalosporins and related substances - antibacterials for systemic use, second-generation cephalosporins - acute streptococcal tonsillitis and pharyngitis. acute bacterial sinusitis. acute otitis media. acute exacerbations of chronic bronchitis. cystitis. pyelonephritis. uncomplicated skin and soft tissue infections. treatment of early lyme disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

milpharm limited - cefuroxime axetil (amorphous) - film coated tablet - 250 milligram - cephalosporins and related substances - antibacterials for systemic use, second-generation cephalosporins - cefuroxime milpharm is indicated for the treatment of the infections listed below in adults and children from the age of 3 months • acute streptococcal tonsillitis and pharyngitis. • acute bacterial sinusitis. • acute otitis media. • acute exacerbations of chronic bronchitis. • cystitis. • pyelonephritis. • uncomplicated skin and soft tissue infections. • treatment of early lyme disease.

United Kingdom - English - myHealthbox

milpharm limited - allopurinol - tablets - 100mg - preparations inhibiting uric acid production - it is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). the main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including lesch-nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase. allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-dha) renal stones

United Kingdom - English - myHealthbox

milpharm limited - allopurinol - tablets - 300mg - preparations inhibiting uric acid production - it is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). the main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including lesch-nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase. allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-dha) renal stones r

Ireland - English - HPRA (Health Products Regulatory Authority)

milpharm limited - aripiprazole - tablets - 5 milligram - other antipsychotics - other antipsychotic - it is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older

Ireland - English - HPRA (Health Products Regulatory Authority)

milpharm limited - aripiprazole - tablets - 10 milligram - other antipsychotics - other antipsychotic - it is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.

Ireland - English - HPRA (Health Products Regulatory Authority)

milpharm limited - aripiprazole - tablets - 15 milligram - other antipsychotics - other antipsychotic - it is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.

Ireland - English - HPRA (Health Products Regulatory Authority)

milpharm limited - aripiprazole - tablets - 30 milligram - other antipsychotics - other antipsychotic - it is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.

Ireland - English - HPRA (Health Products Regulatory Authority)

milpharm limited - pregabalin - capsules hard - 25 milligram - antiepileptics - : antiepileptics, other antiepileptics - it is indicated for the treatment of peripheral and central neuropathic pain in adults; as adjunctive therapy in adults with partial seizures with or without secondary generalisation. and for the treatment of generalised anxiety disorder (gad) in adults.

Ireland - English - HPRA (Health Products Regulatory Authority)

milpharm limited - pregabalin - capsules hard - 75 milligram - antiepileptics - antiepileptics, other antiepileptics - it is indicated: for the treatment of peripheral and central neuropathic pain in adults; as adjunctive therapy in adults with partial seizures with or without secondary generalisation; for the treatment of generalised anxiety disorder (gad) in adults